|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Diet as a risk factor for peripheral arterial disease in the general population: the edinburgh artery study显示文摘 | Thomson Marjory | 1993 | Am J Clin Nutr1993，57，6： | 1 |
| 2 | Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial显示文摘 | Stephen M Davis Geoffrey A Donnan Mark W Parsons Christopher Levi Kenneth S Butcher Andre Peeters P Alan Barber Christopher Bladin Deidre A De Silva Graham Byrnes Jonathan B Chalk John N Fink Thomas E Kimber David Schultz Peter J Hand Judith Frayne Graeme | 2008 | Lancet Neurology2008，，4： | 1 |
| 3 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 4 | New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes显示文摘 | Libby Gillian Donnelly Louise A Donnan Peter T Alessi Dario R Morris Andrew D Evans Josie M M | 2009 | Diabetes Care2009，，： | 1 |
| 5 | Poor glycated haemoglobin control and adverse pregnancy outcomes in type 1 and type 2 diabetes mellitus: Systematic review of observational studies显示文摘 | Inkster Melanie Fahey Tom Donnan Peter | 2006 | BMC Pregnancy and Childbirth2006，，： | 1 |
| 6 | Community-associated Clostridium difficile infection among older people in Tayside, Scotland, is associated with antibiotic exposure and care home residence: cohort study with nested case–control显示文摘 | Charis A. Marwick Ning Yu Michael C. Lockhart Christopher C. McGuigan Camilla Wiuff Peter G. Davey Peter T. Donnan | 2013 | Journal of Antimicrobial Chemotherapy2013，，12： | 1 |
| 7 | Endovascular thrombectomy for stroke: current best practice and future goals显示文摘Endovascular thrombectomy for large vessel ischaemic stroke substantially reduces disability,with recent positive randomised trials leading to guideline changes worldwide.This review discusses in detail the evidence provided by recent randomised trials and metaanalyses,the remaining areas of uncertainty and the future directions for research.The data from existing trials have demonstrated the robust benefit of endovascular thrombectomy for internal carotid and proximal middle cerebral artery occlusions.Uncertainty remains for more distal occlusions where the efficacy of alteplase is greater,less tissue is at risk and the safety of endovascular procedures is less established.Basilar artery occlusion was excluded from the trials,but with a dire natural history and proof of principle that rapid reperfusion is effective,it seems reasonable to continue treating these patients pending ongoing trial results.There has been no evidence of heterogeneity in treatment effect in clinically defined subgroups by age,indeed,those aged>80 years have at least as great an overall reduction in disability and reduced mortality.Similarly there was no heterogeneity across the range of baseline stroke severities included in the trials.Evidence that routine use of general anaesthesia reduces the benefit of endovascular thrombectomy is increasing and conscious sedation is generally preferred unless severe agitation or airway compromise is present.The impact of time delays has become clearer with description of onset to imaging and imaging to reperfusion epochs.Delays in the onset to imaging reduce the proportion of patients with salvageable brain tissue.However,in the presence of favourable imaging,rapid treatment appears beneficial regardless of the onset to imaging time elapsed.Imaging to reperfusion delays lead to decay in the clinical benefit achieved,particularly in those with less robust collateral flow.The brain imaging options to assess prognosis have various advantages and disadvantages,but whatever strategy is employed must be fast.Ongoing trials are investigating extended time windows,using advanced brain imaging selection.There is also a need for further technical advances to maximise rates of complete reperfusion in the minimum time. | Bruce C V Campbell Geoffrey A Donnan Peter J Mitchell Stephen M Davis | 2016 | Stroke & Vascular Neurology2016，1，1： | 1 |
| 8 | 急性卒中影像学研究路径图Ⅱ显示文摘卒中影像学研究组(StrokeImagingResearchGroup,STIR)、美国神经放射学学会和美国神经放射学学会基金会在过去1年多的时间时举办了一系列的工作会议,最后一次会议于2013年3月9日至10日在华盛顿召开的卒中治疗专业学术圆桌会议(Stroke Treatment Academy Industry Roundtable,STAIR)期间举行。 | Max Wintermark Gregory W. Albers Joseph P. Broderick Andrew M. Demchuk Jochen B. Fiebach Jens Fiehler James C. Grotta Gary Houser Tudor G. Jovin Kennedy R. Lees Michael H. Lev David S. Liebeskind Marie Luby Keith W. Muir Mark W. Parsons Rudiger von Kummer Joanna M. Wardlaw Ona Wu Albert J. Yoo Andrei V. Alexandrov Jeffry R. Alger Richard I. Aviv Roland Bammer Jean-Claude Baron Fernando Calamante Bruce C.V. Campbell Trevor C. Carpenter Sφren Christensen William A. Copen Colin P. Derdeyn E. Clarke Haley Jr Pooja Khatri Kohsuke Kudo Maarten G. Lansberg Lawrence L. Latour Ting-Yim Lee Richard Leigh Weili Lin Patrick Lyden Grant Mair Bijoy IC Menon Patrik Michel Robert Mikulik Raul G. Nogueira Left φstergaard Salvador Pedraza Christian H. Riedel Howard A. Rowley Pina C. Sanelli Makoto Sasaki Jeffrey L. Saver Pamela W. Schaefer Peter D. Schellinger Georgios Tsivgoulis Lawrence R. Wechsler Philip M. White Greg Zaharchuk Osama O. Zaidat Stephen M. Davis Geoffrey A. Donnan Anthony J. Furlan Werner Hacke Dong-Wha Kang Chelsea Kidw ell Vincent N. Thijs Gotz Thomalla Steven J. Warach 严晓铭 刘牧 张晶晶 柯开富 | 2014 | 国际脑血管病杂志2014，22，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员